INTELLECTUAL STOCK INVESTOR

[mick]

today/ 01-28-2017/ in full/ #2/ 01-28-2017/ Keeping an Eye on Pharmacyte Biotech Inc (OTCMKTS:PMCB)
By Jermaine Farmer - January 28, 2017

'PharmaCyte Biotech Inc. (PMCB)'

http://oracledispatch.com/2017/01/28/keeping-eye-pharmacyte-biotech-inc-otcmktspmcb/

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is a micro-cap biotech player pushing its way onto the pancreatic cancer treatment scene.

The company was recently featured in a Stock Market Media Group
piece that helps to better define the company’s message.

The basic gist of that message positions
PMCB as an emerging direct competitor with Ely Lilly (LLY)
and its chemotherapy drug, 'gemcitabine.'

PharmaCyte’s alternative is to use its advanced,
inoperable pancreatic cancer therapy,
“which consists of the company’s signature live-cell encapsulation technology, Cell-in-a-Box,
plus low doses of the FDA-approved chemotherapy drug ifosfamide,
in its upcoming clinical trial where it will go head to head with gemcitabine in order to address an unmet medical need.”

Pharmacyte Biotech Inc (OTCMKTS:PMCB) frames itself as a clinical
stage biotechnology company that focuses on developing and commercializing treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology,
known as Cell-in-a-Box.

Its Cell-in-a-Box technology would be used as a platform to treat various types of cancer,
including advanced and inoperable pancreatic cancer, and diabetes.

The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed
in the body to enable the delivery of cancer-killing drugs at the
source of the cancer.

It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and examining the benefits of the
Cell-in-a-Box technology to develop therapies for cancer-based
upon the constituents of the Cannabis plant.

The company was formerly known as Nuvilex, Inc.
and changed its name to PharmaCyte Biotech, Inc.

in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and
is based in Silver Spring, Maryland.

According to company materials,
“PharmaCyte Biotech is a clinical stage biotechnology company
developing therapies for cancer and diabetes based upon a
proprietary cellulose-based live cell encapsulation technology
known as “Cell-in-a-Box®.” T

his technology will be used as a platform upon which therapies
for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug
into its active or “cancer-killing” form.

These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible.

Once implanted, a chemotherapy drug that is normally activated in
the liver (ifosfamide) is given intravenously at one-third the normal dose.

The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted.

When the ifosfamide comes
in contact with the encapsulated cells they act as an
artificial liver and activate the chemotherapy drug at the source
of the cancer.

This “targeted chemotherapy” has proven effective and safe to use
in past clinical trials and results in no side effects.”

http://www.OracleDispatch.com